Neurocrine Biosciences Maps Lifelong CAH Patient Journeys to Highlight Evolving Care Needs
Event summary
- Neurocrine Biosciences presented real-world evidence mapping the lifelong impact of classic congenital adrenal hyperplasia (CAH) at the Endocrine Nurses Society Annual Symposium 2026.
- Analysis of 10 adult CAH patients' records revealed evolving clinical and day-to-day challenges across life stages, from infancy to adulthood.
- Patient journey mapping identified recurring treatment, monitoring, and self-management demands, as well as sex-specific care aspects.
- The study used de-identified electronic medical records from the CAHtalog registry, spanning decades of care across providers and health systems.
The big picture
Neurocrine's analysis underscores the complex, lifelong nature of CAH and the need for personalized, stage-specific care. The findings come as the company continues to expand its portfolio in rare endocrine disorders, following the 2024 FDA approval of its CRF1 antagonist CRENESSITY. The study highlights the growing importance of real-world evidence in shaping treatment approaches for chronic, multi-faceted conditions.
What we're watching
- Clinical Integration
- How healthcare professionals will incorporate these insights into anticipating and addressing evolving CAH patient needs.
- Therapeutic Advancements
- Whether Neurocrine's CRENESSITY and other treatments can leverage these findings to improve long-term CAH management.
- Data Utilization
- The pace at which real-world evidence from the CAHtalog registry will inform future CAH research and treatment strategies.
